Sunlenca is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Gilead Sciences. The primary component is Lenacapavir Sodium.
Product ID | 61958-3001_e2f725c8-d250-42e1-bb62-249cf99bcb28 |
NDC | 61958-3001 |
Product Type | Human Prescription Drug |
Proprietary Name | Sunlenca |
Generic Name | Lenacapavir Sodium |
Dosage Form | Tablet, Film Coated |
Route of Administration | ORAL |
Marketing Start Date | 2022-12-22 |
Marketing Category | NDA / |
Application Number | NDA215974 |
Labeler Name | Gilead Sciences |
Substance Name | LENACAPAVIR SODIUM |
Active Ingredient Strength | 300 mg/1 |
NDC Exclude Flag | N |
Listing Certified Through | 2024-12-31 |
Marketing Start Date | 2022-12-22 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
61958-3001 | Sunlenca | LENACAPAVIR SODIUM |
61958-3002 | Sunlenca | LENACAPAVIR SODIUM |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
SUNLENCA 88823358 not registered Live/Pending |
Gilead Sciences Ireland UC 2020-03-05 |